{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T03:20:28Z","timestamp":1787541628685,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10620-026-09773-1","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:31:54Z","timestamp":1772800314000},"page":"3400-3408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Severe Influenza-Related Outcomes in Patients with Inflammatory Bowel Disease on Immunosuppressive Therapy: A Propensity-Matched Cohort Analysis"],"prefix":"10.1007","volume":"71","author":[{"given":"Mohamed H.","family":"Eldesouki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Alkasabrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Y.","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eslam","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saqr","family":"Alsakarneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis A.","family":"Farraye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana G.","family":"Hashash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"9773_CR1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.mpmed.2021.09.015","volume":"49","author":"CS Tyrrell","year":"2021","unstructured":"Tyrrell CS, Allen JLY, Gkrania-Klotsas E. Influenza: epidemiology and hospital management. Medicine (Abingdon). 2021;49:797\u2013804. https:\/\/doi.org\/10.1016\/j.mpmed.2021.09.015.","journal-title":"Medicine (Abingdon)."},{"key":"9773_CR2","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.amjmed.2007.10.040","volume":"121","author":"MB Rothberg","year":"2008","unstructured":"Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med. 2008;121:258\u2013264. https:\/\/doi.org\/10.1016\/j.amjmed.2007.10.040.","journal-title":"Am J Med."},{"key":"9773_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40471-018-0136-1","volume":"5","author":"A Gordon","year":"2018","unstructured":"Gordon A, Reingold A. The burden of influenza: a complex problem. Curr Epidemiol Rep. 2018;5:1\u20139. https:\/\/doi.org\/10.1007\/s40471-018-0136-1.","journal-title":"Curr Epidemiol Rep."},{"key":"9773_CR4","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1093\/cid\/ciae547","volume":"80","author":"AC O'Halloran","year":"2025","unstructured":"O\u2019Halloran AC, Millman AJ, Holstein R et al. The burden of all-cause mortality following influenza-associated hospitalizations: influenza hospitalization surveillance network, 2010\u20132019. Clin Infect Dis. 2025;80:e43\u2013e45. https:\/\/doi.org\/10.1093\/cid\/ciae547.","journal-title":"Clin Infect Dis."},{"key":"9773_CR5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.cgh.2018.07.013","volume":"17","author":"L Beaugerie","year":"2019","unstructured":"Beaugerie L, Kirchgesner J. Balancing benefit vs risk of immunosuppressive therapy for individual patients with inflammatory Bowel diseases. Clin Gastroenterol Hepatol. 2019;17:370\u2013379. https:\/\/doi.org\/10.1016\/j.cgh.2018.07.013.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"9773_CR6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/MIB.0b013e3182a827d2","volume":"20","author":"M Dave","year":"2014","unstructured":"Dave M, Purohit T, Razonable R et al. Opportunistic infections due to inflammatory bowel disease therapy. Inflamm Bowel Dis. 2014;20:196\u2013212. https:\/\/doi.org\/10.1097\/MIB.0b013e3182a827d2.","journal-title":"Inflamm Bowel Dis."},{"key":"9773_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cgh.2019.02.044","volume":"18","author":"S Singh","year":"2020","unstructured":"Singh S, Facciorusso A, Dulai PS et al. Comparative risk of serious infections with biologic and\/or immunosuppressive therapy in patients with inflammatory Bowel diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020;18:69-81.e3. https:\/\/doi.org\/10.1016\/j.cgh.2019.02.044.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"9773_CR8","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","volume":"134","author":"M Toruner","year":"2008","unstructured":"Toruner M, Loftus EV Jr, Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929\u2013936. https:\/\/doi.org\/10.1053\/j.gastro.2008.01.012.","journal-title":"Gastroenterology."},{"key":"9773_CR9","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.3748\/wjg.v27.i27.4276","volume":"27","author":"V Craviotto","year":"2021","unstructured":"Craviotto V, Furfaro F, Loy L et al. Viral infections in inflammatory bowel disease: Tips and tricks for correct management. World J Gastroenterol. 2021;27:4276\u20134297. https:\/\/doi.org\/10.3748\/wjg.v27.i27.4276.","journal-title":"World J Gastroenterol."},{"key":"9773_CR10","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/ibd\/izy243","volume":"25","author":"A Tinsley","year":"2019","unstructured":"Tinsley A, Navabi S, Williams ED et al. Increased risk of influenza and influenza-related complications among 140,480 patients with inflammatory bowel disease. Inflamm Bowel Dis. 2019;25:369\u2013376. https:\/\/doi.org\/10.1093\/ibd\/izy243.","journal-title":"Inflamm Bowel Dis."},{"key":"9773_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00284-023-03305-0","volume":"80","author":"T Dehghani","year":"2023","unstructured":"Dehghani T, Gholizadeh O, Daneshvar M et al. Association between inflammatory Bowel disease and viral infections. Curr Microbiol. 2023;80:195. https:\/\/doi.org\/10.1007\/s00284-023-03305-0.","journal-title":"Curr Microbiol."},{"key":"9773_CR12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000437066","volume":"33","author":"JF Rahier","year":"2015","unstructured":"Rahier JF. Management of IBD patients with current immunosuppressive therapy and concurrent infections. Dig Dis. 2015;33:50\u201356. https:\/\/doi.org\/10.1159\/000437066.","journal-title":"Dig Dis."},{"key":"9773_CR13","doi-asserted-by":"publisher","first-page":"4610","DOI":"10.1111\/bph.16511","volume":"181","author":"A Kumar","year":"2024","unstructured":"Kumar A, Mark ZF, Carbajal MP et al. The protein disulfide isomerase A3 and osteopontin axis promotes influenza-induced lung remodelling. Br J Pharmacol. 2024;181:4610\u20134627. https:\/\/doi.org\/10.1111\/bph.16511.","journal-title":"Br J Pharmacol."},{"key":"9773_CR14","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000840","volume":"16","author":"S Alsakarneh","year":"2025","unstructured":"Alsakarneh S, Ramirez Ramirez O, Hayney MS et al. Patients with inflammatory bowel disease are at increased risk of respiratory syncytial virus infections after severe acute respiratory syndrome coronavirus 2 infection: a propensity-matched cohort analysis. Clin Transl Gastroenterol. 2025;16:e00840. https:\/\/doi.org\/10.14309\/ctg.0000000000000840.","journal-title":"Clin Transl Gastroenterol."},{"key":"9773_CR15","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jinf.2023.01.006","volume":"86","author":"YW Tsai","year":"2023","unstructured":"Tsai YW, Tsai CF, Wu JY et al. The risk of methicillin-resistant Staphylococcus aureus infection following COVID-19 and influenza: a retrospective cohort study from the TriNetX network. J Infect. 2023;86:256\u2013308. https:\/\/doi.org\/10.1016\/j.jinf.2023.01.006.","journal-title":"J Infect."},{"key":"9773_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13092495","author":"S Alsakarneh","year":"2024","unstructured":"Alsakarneh S, Jaber F, Qasim H et al. Increased risk of breakthrough SARS-CoV-2 infections in patients with colorectal cancer: a population-based propensity-matched analysis. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13092495.","journal-title":"J Clin Med."},{"key":"9773_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056944","volume":"8","author":"SL Kristensen","year":"2013","unstructured":"Kristensen SL, Ahlehoff O, Lindhardsen J et al. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death\u2014a Danish nationwide cohort study. PLoS ONE. 2013;8:e56944. https:\/\/doi.org\/10.1371\/journal.pone.0056944.","journal-title":"PLoS ONE."},{"key":"9773_CR18","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1111\/apt.18275","volume":"60","author":"K M\u00e5rild","year":"2024","unstructured":"M\u00e5rild K, S\u00f6derling J, Axelrad J et al. A nationwide cohort study of inflammatory bowel disease, histological activity and fracture risk. Aliment Pharmacol Ther. 2024;60:1549\u20131560. https:\/\/doi.org\/10.1111\/apt.18275.","journal-title":"Aliment Pharmacol Ther."},{"key":"9773_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101722","volume":"53","author":"K M\u00e5rild","year":"2022","unstructured":"M\u00e5rild K, S\u00f6derling J, Stephansson O et al. Histological remission in inflammatory bowel disease and risk of adverse pregnancy outcomes: a nationwide study. EClinicalMedicine. 2022;53:101722. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101722.","journal-title":"EClinicalMedicine."},{"key":"9773_CR20","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.14309\/ajg.0000000000003465","volume":"120","author":"GR Lichtenstein","year":"2025","unstructured":"Lichtenstein GR, Loftus EV, Afzali A et al. ACG Clinical Guideline: management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2025;120:1225\u20131264. https:\/\/doi.org\/10.14309\/ajg.0000000000003465.","journal-title":"Am J Gastroenterol."},{"key":"9773_CR21","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA et al. ACG Clinical Guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114:384\u2013413. https:\/\/doi.org\/10.14309\/ajg.0000000000000152.","journal-title":"Am J Gastroenterol."},{"key":"9773_CR22","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/164_2021_550","volume":"272","author":"G Handley","year":"2022","unstructured":"Handley G, Hand J. Adverse Effects of Immunosuppression: Infections. Handb Exp Pharmacol. 2022;272:287\u2013314. https:\/\/doi.org\/10.1007\/164_2021_550.","journal-title":"Handb Exp Pharmacol."},{"key":"9773_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2020-000573","author":"PM Irving","year":"2021","unstructured":"Irving PM, de Lusignan S, Tang D et al. Risk of common infections in people with inflammatory bowel disease in primary care: a population-based cohort study. BMJ Open Gastroenterol. 2021. https:\/\/doi.org\/10.1136\/bmjgast-2020-000573.","journal-title":"BMJ Open Gastroenterol."},{"key":"9773_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/ceg.S42514","volume":"6","author":"DJ Stobaugh","year":"2013","unstructured":"Stobaugh DJ, Deepak P, Ehrenpreis ED. Hospitalizations for vaccine preventable pneumonias in patients with inflammatory bowel disease: a 6-year analysis of the Nationwide Inpatient Sample. Clin Exp Gastroenterol. 2013;6:43\u201349. https:\/\/doi.org\/10.2147\/ceg.S42514.","journal-title":"Clin Exp Gastroenterol."},{"key":"9773_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.677957","volume":"12","author":"M Zhang","year":"2021","unstructured":"Zhang M, Bai X, Cao W et al. The influence of corticosteroids, immunosuppressants and biologics on patients with inflammatory Bowel diseases, psoriasis and rheumatic diseases in the era of COVID-19: a review of current evidence. Front Immunol. 2021;12:677957. https:\/\/doi.org\/10.3389\/fimmu.2021.677957.","journal-title":"Front Immunol."},{"key":"9773_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13613-020-0642-4","volume":"10","author":"MJ Tsai","year":"2020","unstructured":"Tsai MJ, Yang KY, Chan MC et al. Impact of corticosteroid treatment on clinical outcomes of influenza-associated ARDS: a nationwide multicenter study. Ann Intensive Care. 2020;10:26. https:\/\/doi.org\/10.1186\/s13613-020-0642-4.","journal-title":"Ann Intensive Care."},{"key":"9773_CR27","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1177\/1756283x10366368","volume":"3","author":"M Shale","year":"2010","unstructured":"Shale M, Czub M, Kaplan GG et al. Anti-tumor necrosis factor therapy and influenza: keeping it in perspective. Therap Adv Gastroenterol. 2010;3:173\u2013177. https:\/\/doi.org\/10.1177\/1756283x10366368.","journal-title":"Therap Adv Gastroenterol."},{"key":"9773_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/1744666X.2022.2014323","volume":"18","author":"MA Adas","year":"2022","unstructured":"Adas MA, Alveyn E, Cook E et al. The infection risks of JAK inhibition. Expert Rev Clin Immunol. 2022;18:253\u2013261. https:\/\/doi.org\/10.1080\/1744666X.2022.2014323.","journal-title":"Expert Rev Clin Immunol."},{"key":"9773_CR29","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","volume":"8","author":"JF Rahier","year":"2014","unstructured":"Rahier JF, Magro F, Abreu C et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443\u2013468. https:\/\/doi.org\/10.1016\/j.crohns.2013.12.013.","journal-title":"J Crohns Colitis."},{"key":"9773_CR30","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.14309\/ajg.0000000000003541","volume":"120","author":"FA Farraye","year":"2025","unstructured":"Farraye FA, Melmed GY, Lichtenstein GR et al. ACG Clinical Guideline Update: preventive care in inflammatory Bowel disease. Am J Gastroenterol. 2025;120:1447\u20131473. https:\/\/doi.org\/10.14309\/ajg.0000000000003541.","journal-title":"Am J Gastroenterol."},{"key":"9773_CR31","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.cgh.2024.12.011","volume":"23","author":"F Caldera","year":"2025","unstructured":"Caldera F, Kane S, Long M et al. AGA clinical practice update on noncolorectal cancer screening and vaccinations in patients with inflammatory bowel disease: expert review. Clin Gastroenterol Hepatol. 2025;23:695\u2013706. https:\/\/doi.org\/10.1016\/j.cgh.2024.12.011.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"9773_CR32","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/ecco-jcc\/jjad182","volume":"18","author":"Z Liu","year":"2024","unstructured":"Liu Z, Alexander JL, Yee Eng K et al. Antibody responses to influenza vaccination are diminished in patients with inflammatory bowel disease on infliximab or tofacitinib. J Crohns Colitis. 2024;18:560\u2013569. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad182.","journal-title":"J Crohns Colitis."},{"key":"9773_CR33","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/cid\/ciy874","volume":"68","author":"TM Uyeki","year":"2019","unstructured":"Uyeki TM, Bernstein HH, Bradley JS et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa. Clin Infect Dis. 2019;68:895\u2013902. https:\/\/doi.org\/10.1093\/cid\/ciy874.","journal-title":"Clin Infect Dis."},{"key":"9773_CR34","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/ibd\/izz164","volume":"26","author":"F Caldera","year":"2020","unstructured":"Caldera F, Hillman L, Saha S et al. Immunogenicity of high dose influenza vaccine for patients with inflammatory Bowel disease on anti-TNF monotherapy: a randomized clinical trial. Inflamm Bowel Dis. 2020;26:593\u2013602. https:\/\/doi.org\/10.1093\/ibd\/izz164.","journal-title":"Inflamm Bowel Dis."},{"key":"9773_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030455","author":"L Doornekamp","year":"2020","unstructured":"Doornekamp L, Goetgebuer RL, Schmitz KS et al. High immunogenicity to influenza vaccination in Crohn\u2019s disease patients treated with Ustekinumab. Vaccines (Basel). 2020. https:\/\/doi.org\/10.3390\/vaccines8030455.","journal-title":"Vaccines (Basel)."},{"key":"9773_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2024-001370","author":"G Nakafero","year":"2024","unstructured":"Nakafero G, Grainge MJ, Card T et al. Uptake, safety and effectiveness of inactivated influenza vaccine in inflammatory bowel disease: a UK-wide study. BMJ Open Gastroenterol. 2024. https:\/\/doi.org\/10.1136\/bmjgast-2024-001370.","journal-title":"BMJ Open Gastroenterol."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09773-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-09773-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09773-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T03:01:39Z","timestamp":1787540499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-09773-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["9773"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-09773-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7936452\/v1","asserted-by":"object"}]},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The contributing authors have no financial, professional, personal, or other conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Farraye has served as a Consultant for Astellas, Avalo Therapeutics, Bausch, BMS, Braintree Labs, Fresenius Kabi, GI Reviewers, IBD Educational Group, Iterative Health, Janssen, Pharmacosmos, Pfizer, Sandoz Immunology, Viatris.He sits on a DSMB for Eli Lilly and Moon Lake.","order":2,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}}]}}